Brief

GlobalData projects 139.2 million dyslipidemia cases worldwide by 2035

The forecast shows a 0.58% annual growth, highlighting regional differences in risk factors.

By Felo News Desk · Published Sat, 10 Oct 2026 06:52:20 GMT

GlobalData’s latest epidemiology report estimates that diagnosed prevalent cases of dyslipidemia in the seven‑major‑market (7MM) group will increase from 131.6 million in 2025 to 139.2 million in 2035, a 0.58% annual growth rate.

The United States is projected to have the highest number of cases, reaching just over 61.4 million by 2035. Japan and the five‑EU bloc (France, Germany, Italy, Spain, the UK) are expected to account for about 15.3 million and 62.6 million cases respectively.

Alia Rafiq, Senior Epidemiologist at GlobalData, attributes Japan’s and France’s lower prevalence to reduced obesity rates and healthier lipid profiles, noting a higher frequency of CETP gene variants that raise HDL‑C in Japanese populations. In contrast, the UK shows the fastest growth rate and the highest diagnosed prevalence in 2025, driven by a Western diet, limited exercise, high obesity, and a strong burden of cardiovascular disease, according to NHS data.

Key facts

Diagnosed dyslipidemia cases in the 7MM are forecast to reach 139.2 million by 2035. (globaldata.com)
The United States will have the largest share with about 61.4 million cases in 2035. (globaldata.com)
Japan and the five‑EU bloc are projected to have 15.3 million and 62.6 million cases respectively. (globaldata.com)
The UK has the highest annual growth rate of diagnosed cases among the 7MM. (globaldata.com)
Low prevalence in Japan and France is linked to lower obesity rates and genetic factors. (globaldata.com)